Skip to main content

Table 1 Patients’ characteristics at PMBCL diagnosis

From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

 

Overall cohort

Rituximab treatment

No Rituximab treatment

P value

Patient number, N (%)

80 (100)

45 (56)

35 (44)

/

Age at diagnosis, years

37 (18–64)

38 (19–64)

35 (18–58)

0.485

Gender, N (%)

   

0.360

 Male

33 (41)

21 (47)

12 (34)

 Female

47 (59)

24 (53)

23 (66)

B symptoms, N (%)

40 (50)

26 (58)

14 (40)

0.176

LDH elevated, N (%)a

58 (79)

33 (75)

25 (86)

0.841

LDH level at diagnosis, median U/l (range)

329 (145–1450)

327 (112–1277)

376 (145–1450)

0.439

Ann Arbor stage, N (%)

   

0.396

 I

11 (14)

8 (18)

3 (8)

 II

49 (61)

26 (58)

23 (66)

 III

15 (19)

7 (15)

8 (23)

 IV

5 (6)

4 (9)

1 (3)

Extranodal sites involved, N (%)

   

0.536

 no

68 (85)

37 (82)

31 (89)

 yes

12 (15)

8 (18)

4 (11)

ECOG, N (%)

   

0.344

 0

58 (73)

33 (73)

25 (71)

 1

20 (25)

12 (27)

8 (23)

 2

2 (2)

0 (0)

2 (6)

IPIb, N (%)

   

0.397

 Low risk

50 (66)

32 (71)

18 (58)

 Low-intermediate risk

13 (17)

7 (16)

6 (19)

 High-intermediate risk

12 (16)

5 (11)

7 (23)

High risk

1 (1)

1 (2)

0 (0)

  1. aLDH was not available in 1 and 6 patients in the rituximab treatment and no rituximab treatment group, respectively. bIPI was not available in 4 patients in the no rituximab treatment group. ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase